SBIR Phase I: Industrial-Scale Technology for Drug Development in Mature Human Fat Cells

SBIR 第一阶段：成熟人类脂肪细胞药物开发的工业规模技术

• 批准号: 2322443
• 负责人: Benjamin Pope
• 金额: $ 27.5万
• 依托单位: MELLICELL, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2024
• 资助国家: 美国
• 起止时间: 2024-01-15 至 2024-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2322443&HistoricalAwards=false
• 关键词: SBIR; Phase; Industrial; Scale; Technology; SBIR; Phase; Industrial; Scale; Technology

The broader impact of this Small Business Innovation Research (SBIR) Phase I project is to increase the scale and throughput of novel technology with the potential to enable the discovery and development of next-generation therapeutics for obesity and the array of associated medical conditions that can be ameliorated with weight loss. This technology could also be expanded to therapeutic development to address other reproductive and ageing disorders characterized by diseased fat cells.This project may enable drug development in human fat cells at a previously unattainable quality and scale. For the last 50 years, the first stage of drug development in adipocytes has been limited by the lack of a tractable system that faithfully reproduces the clinical features of mature fat cells. The technology in this project could efficiently turn adult human stem cells into fat cells and accelerate their maturation thousands of times relative to conventional methods. Adipocytes generated by this new technology may more closely match the cellular shape and size, gene expression profile, and function of mature fat cells in adults. Scaling the technology will require development of novel devices for automation and the design and testing of customized protocols. Success will be determined by measures of manufacturing quality control and specific properties of mature human fat tissue.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛影响是增加新技术的规模和吞吐量，以便能够发现和开发下一代肥胖症的下一代治疗剂以及可以随体重减轻而改善的相关医疗条件的数组。该技术也可以扩展到治疗性开发，以解决以患病细胞为特征的其他生殖和衰老疾病。该项目可能使人类脂肪细胞的药物发育能够以先前无法实现的质量和规模。在过去的50年中，脂肪细胞中药物发育的第一阶段受到缺乏忠实地再现成熟脂肪细胞的临床特征的可拖动系统的限制。该项目中的技术可以有效地将成年人类干细胞变成脂肪细胞，并相对于常规方法加速其成熟数千次。这项新技术产生的脂肪细胞可能更匹配成人成人脂肪细胞的细胞形状和大小，基因表达谱以及功能。扩展技术将需要开发新型设备以进行自动化以及定制协议的设计和测试。成功将取决于制造质量控制和成熟人类脂肪组织的特定特性的衡量标准。该奖项反映了NSF的法定任务，并且使用基金会的知识分子优点和更广泛的影响评估标准，认为值得通过评估来获得支持。